We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

QIAGEN Acquires ESE GmbH

News   Jan 13, 2010

 
QIAGEN Acquires ESE GmbH
 
 
 

RELATED ARTICLES

Bioactive Agents Improve Synthetic Bone Substitutes

News

Synthetic bone substitutes are promising materials for bone defect repair, but their efficacy can be substantially improved by bioactive agents such as growth factors. In a new study, researchers have modified beta-tricalcium phosphate (β-TCP) with increasing quantities of bone morphogenetic protein 2 (BMP-2) derived from E. coli and shown improved bone healing.

READ MORE

Limitations of Health Reports From Direct-to-Consumer Genetic Tests Are Identified

News

According to study findings presented at the American Society of Human Genetics (ASHG) 2019 Annual Meeting, health reports from direct-to-consumer (DTC) genetic tests that adopt a limited variant screening approach are producing clinically false-negative results.

READ MORE

Time To Say Goodbye… to the “Household Measure” BMI?

News

A new study published in PLOS Biology sees an international collaboration of academia and industry experts introduce a novel "revolutionary" approach towards personalized and precision biomedicine, moving away from the "classic" morphometric BMI.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Diagnostics Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE